Literature DB >> 23707778

Long-term follow-up reveals low incidence of colorectal cancer, but frequent need for resection, among Australian patients with inflammatory bowel disease.

Christian P Selinger1, Jane M Andrews2, Andrew Titman3, Ian Norton4, D Brian Jones5, Charles McDonald5, Gavin Barr5, Warwick Selby6, Rupert W Leong7.   

Abstract

BACKGROUND & AIMS: Inflammatory bowel disease can require surgical resection and also lead to colorectal cancer (CRC). We investigated the cumulative incidence of resection surgeries and CRC among patients with ulcerative colitis (UC) or Crohn's disease (CD).
METHODS: We analyzed data from a cohort of patients who participated in an inflammatory bowel disease study (504 with UC and 377 with CD) at 2 academic medical centers in Sydney, Australia from 1977 to 1992 (before the development of biologic therapies). We collected follow-up data on surgeries and development of CRC from hospital and community medical records or via direct contact with patients during a median time period of 14 years. Cumulative incidences of resection surgeries and CRC were calculated by competing risk survival analysis.
RESULTS: Among patients with UC, CRC developed in 24, for a cumulative incidence of 1% at 10 years (95% confidence interval [CI], 0%-2%), 3% at 20 years (95% CI, 1%-5%), and 7% at 30 years (95% CI, 4%-10%). Their cumulative incidence of colectomy was 15% at 10 years (95% CI, 11%-19%), 26% at 20 years (95% CI, 21%-30%), and 31% at 30 years (95% CI, 25%-36%). Among patients with CD, 5 of 327 with colon disease developed CRC, with a cumulative incidence of CRC of 1% at 10 years (95% CI, 0%-2%), 1% at 20 years (95% CI, 0%-2%), and 2% at 30 years (95% CI, 0%-4%). Among all patients with CD, the cumulative incidence of resection was 32% at 5 years (95% CI, 27%-37%), 43% at 10 years (95% CI, 37%-49%), and 53% at 15 years (95% CI, 46%-58%). Of these 168 subjects, 42% required a second resection within 15 years of the first surgery (95% CI, 33%-50%).
CONCLUSIONS: Patients with UC have a low incidence of CRC during a 30-year period (7% or less); the incidence among patients with CD is even lower. However, almost one-third of patients with UC and about 50% of those with CD will require surgery.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colon Cancer Risk; Prognosis; Therapy; Treatment

Mesh:

Year:  2013        PMID: 23707778     DOI: 10.1016/j.cgh.2013.05.017

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  17 in total

Review 1.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 2.  Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management.

Authors:  Shailja C Shah; Steven H Itzkowitz
Journal:  Gastroenterology       Date:  2021-10-29       Impact factor: 22.682

Review 3.  Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.

Authors:  Torsten Kucharzik; Sibylle Koletzko; Klaus Kannengiesser; Axel Dignass
Journal:  Dtsch Arztebl Int       Date:  2020-08-17       Impact factor: 5.594

Review 4.  Inflammatory bowel disease and anxiety: links, risks, and challenges faced.

Authors:  Ayman S Bannaga; Christian P Selinger
Journal:  Clin Exp Gastroenterol       Date:  2015-03-23

5.  The impact of COVID-19 pandemic in the colorectal cancer prevention.

Authors:  Giovanna Del Vecchio Blanco; Emma Calabrese; Livia Biancone; Giovanni Monteleone; Omero Alessandro Paoluzi
Journal:  Int J Colorectal Dis       Date:  2020-06-04       Impact factor: 2.571

6.  The association between new generation oral contraceptive pill and the development of inflammatory bowel diseases.

Authors:  Santosh Sanagapalli; Yanna Ko; Viraj Kariyawasam; Siew C Ng; Whitney Tang; Hithanadura Janaka de Silva; Minhu Chen; Kaichun Wu; Satimai Aniwan; Ka Kei Ng; David Ong; Qin Ouyang; Ida Hilmi; Marcellus Simadibrata; Pises Pisespongsa; Saranya Gopikrishna; Rupert W Leong
Journal:  Intest Res       Date:  2018-07-27

7.  Management of Low Rectal Cancer Complicating Ulcerative Colitis: Proposal of a Treatment Algorithm.

Authors:  Bruno Sensi; Giulia Bagaglini; Vittoria Bellato; Daniele Cerbo; Andrea Martina Guida; Jim Khan; Yves Panis; Luca Savino; Leandro Siragusa; Giuseppe S Sica
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

Review 8.  Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Chelle L Wheat; Kindra Clark-Snustad; Beth Devine; David Grembowski; Timothy A Thornton; Cynthia W Ko
Journal:  Gastroenterol Res Pract       Date:  2016-05-16       Impact factor: 2.260

9.  Medication non-adherence in inflammatory bowel diseases is associated with disability.

Authors:  Jonathan Perry; Andy Chen; Viraj Kariyawasam; Glen Collins; Chee Choong; Wei Ling Teh; Nikola Mitrev; Friedbert Kohler; Rupert Wing Loong Leong
Journal:  Intest Res       Date:  2018-10-10

10.  Risk of colorectal cancer in a population-based study 20 years after diagnosis of ulcerative colitis: results from the IBSEN study.

Authors:  Pasquale Klepp; Stephan Brackmann; Milada Cvancarova; Marte Lie Hoivik; Øistein Hovde; Magne Henriksen; Gert Huppertz-Hauss; Tomm Bernklev; Ole Hoie; Iril Kempski-Monstad; Inger Camilla Solberg; Njaal Stray; Jorgen Jahnsen; Morten H Vatn; Bjorn Moum
Journal:  BMJ Open Gastroenterol       Date:  2020-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.